Miyawaki E, Meah Y, Koller W C
Department of Neurology, University of Kansas Medical Center, Kansas City 66160-7314, USA.
Clin Neuropharmacol. 1997 Aug;20(4):300-10. doi: 10.1097/00002826-199708000-00002.
We review recent reports suggesting that use of selective serotonergic agents that either inhibit synaptic reuptake or have specific serotonin receptor affinities may benefit a variety of motor disturbances in Parkinson's disease. The complex, mixed motoric effects of these agents in Parkinson's disease have not allowed for a consistent view on the interrelationship between dopamine and serotonin (5HT) in motor control but may speak to the nature of dysregulated neurotransmission in the disease.
